Skip to content

Bayer opts not to pursue Schiff acquisition

Bayer HealthCare is stepping away from its proposed deal to acquire Schiff Nutritional International after Reckitt Benckiser Group came in with a higher bid.

Table of Contents

NEW YORK — Bayer HealthCare is stepping away from its proposed deal to acquire Schiff Nutritional International after Reckitt Benckiser Group came in with a higher bid.

In a filing with the Securities and Exchange Commission on Monday, Bayer AG said its board has decided not to up its $34-per-share cash offer to buy Schiff in a $1.2 billion deal.

"Bayer AG’s board of management continues to believe that the merger transaction would represent a logical and strategic addition for Bayer’s Consumer Care business," the company stated in the Nov. 19 SEC filing. "However, it came to the conclusion that entering a competitive bidding process … would result in a price outside Bayer’s set financial criteria. Having completed a number of successful acquisitions, Bayer plans to continue its strategy to augment organic growth with strategic bolt-on acquisitions."

Bayer announced the agreement to acquire Schiff on Oct. 30, saying the deal would boost its Consumer Care business by adding some well-known vitamin and dietary supplement brands — including MegaRed, Move Free and Airborne — and boosting its presence in the U.S. market. The transaction was expected to close by the end of this year.

However, on Nov. 16, U.K.-based Reckitt Benckiser unveiled a $1.4 billion tender offer to acquire all of the outstanding shares Schiff. Reckitt Benckiser said its offer of $42 per share in cash represented a premium of 23.5% over Bayer’s $34-per-share bid.

Comments

Latest